Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD2389 Alone and With Itraconazole in Healthy Participants
NCT06846528Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD2389 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by AstraZeneca. Primary endpoints: Maximum observed drug concentration at Day 8, Area under concentration-time curve from time zero to infinity at Day 8 and 1 more. Started Feb 2025; status: completed.
02
Drugs
AZD2389
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06846528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846528.